

Cyprus Urological Association

EXPERTS FORUM in UROLOGY

Programme

5th SPRING
UROLOGICAL
SYMPOSIUM
19-21 APRIL
2024

MIRAMARE HOTEL
LIMASSOL, CY



www.cau.org.cy





BetmigaTM

mirabegron



BET/ADV/1/06/23

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναμφισβήτητο
ΟΜΕΤ τις αναπληρωμένες ενδείξεις για ΟΔΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ ΓΙΑ ΤΟ ΟΠΟΙΟ ΑΠΑΙΤΕΙΤΑΙ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ

Ελλάδα

Betmiga 25 mg δισκία παρατεταμένης αποδέσμευσης ΛΤ 42,36€

Betmiga 50 mg δισκία παρατεταμένης αποδέσμευσης ΛΤ 32,73€

Κύπρος

Betmiga 25 mg δισκία παρατεταμένης αποδέσμευσης 45,74€

Betmiga 50 mg δισκία παρατεταμένης αποδέσμευσης 40,79€

Περισσότερη πληροφορία διατίθεται από τον ΚΑΚ, κατόπιν απήσεως, ή περιλαμβάνονται στη συνοδευτική περιγραφή χαρακτηριστικών του προϊόντος, το Φύλλο Οδηγιών Χρήσης του φαρμάκου.



Astellas Pharmaceuticals A.E.B.E.
Αγναλάου 6-8, 151 23 Μαρούσι Αθήνα.
Τηλ. 210 8189 900, Fax: 216 8008 998
www.astellas.com.gr

Τοπικός Αντιπρόσωπος/
Διανομέας προϊόντων Astellas στην Κύπρο:
Novagem Ltd, Τηλ: 00357 22483858

On behalf of the board of directors of Cyprus Urological Association (CAU) and members of the Organizing we are pleased to announce **the 5th Spring Urological Symposium, which is being held in April 19-21 2024, in Limassol**, a very modern city which will again serve as a springboard to strongly advance the CAU initiative for world-wide advancement of Urology in both scientific and clinical aspects, thus "Defining the Future of Urology".

Since its foundation in 1993, CAU has sought to associate and affiliate all Urologists into one organization, physicians and scientists who are engaged in, or interested in, the techniques for Urology surgery, and modern Urological investigations approaches. Our vision is to provide comfortable care everywhere through education, research and knowledge together in a flexible, innovative and open Society.

The aim of the meeting is to promote the exchange of expert knowledge in the continually advancing field of Urology. The scientific program includes State-of-the-Art Lectures the latest developments in clinical research, the sophisticated well-documented clinical methods and technologies as well.

Eminent and distinguished colleagues from continental Europe, Cyprus and other affiliated societies will honour us with their presence and present the most advanced approaches to diagnostic, therapeutic and research topics covering the whole spectrum of Urology. Friendly Societies invited to participate the meeting. You can participate in very active discussions and cutting-edge lectures by the invited world's top scientists and Urologists as hear all the advances of scientific and clinical Urology.

CAU 2024 will also give us the time and opportunities for networking. While enjoying our outstanding scientific program, CAU's Symposium is the place to network with your peers, meet old friends and make new ones.

We very much expect you to enjoy this exciting Urological Symposium set in Limassol!

Dr. Stavros Charalampous MD, PhD, FEBU

CAU President

4th SPRING UROLOGICAL SYMPOSIUM

ORGANIZED BY:



CYPRUS UROLOGICAL ASSOCIATION

tel.: 25587711

email: office@cau.org.cy

www.cau.org.cy

IN COLLABORATION WITH:



**EAU, HUA, SIU, ICS, ESFU,
PACs, LUS, INUS**

COMMITTEES:

BOARD OF DIRECTORS

President

Stavros Charalampous

Vice-President

Zafiro Kyriazi

General Secretary

Petros Tsafrakides

Treasure

Ziad Imbrahim

Members

Demetris Costi

Panayiotis Sakkas

Angelos Econimides

ORGANIZING COMMITTEE

President

Stavros Charalampous

Vice-President

Zafiro Kyriazi

Secretary

Petros Tsafrakides

Members

Ziad Milad

Panayiotis Sakkas

Dimitris Costi

Constantinos Tryfonos

Angelos Economides

SCIENTIFIC COMMITTEE

Presidents

Stavros Gravas

Petros Tsafrakides

Vice-President

Chrysanthos Kouriefs

Members

Chris Poulis

Vasilis Adamou

Prodromos Philippou

Theocharis Karaolides

Costantinos Eliades

Nicolas Nicolaou

Antonis Koumis

HONORARY COMMITTEE

Spyros Eliades

Mikis Christofides

Costas Mavrommatis

16.00–17.00	Registrations - Welcome coffee Urological Cancers Session	P.T. Hadjigeorgiou co Ltd 
17.00–18.30	Prostate Cancer <i>Chairs: Constantinos Eliades, Simos Malas</i>	
17.00–17.15	Targeted Biopsy and Overgrading of MRI lesions in Prostate Cancer: Does it Lead to Overtreatment? <i>Andreas Kyriakides CY</i>	
17.15–17.30	Lutetium Theragnostics <i>Emmanouil Alevroudis CY</i>	
17.30–17.45	The urologist's perspective on active surveillance <i>Theocharis Karaolides CY</i>	
17.45–18.00	New treatment modalities in advance prostate cancer Management <i>Demetris Vomvas CY</i>	
18.00–18.20	Q&A discussion	
18.20–19.30	Bladder Cancer <i>Chairs: Mikis Christofides, Petros Kitsios</i>	
18.20–18.40	Imaging for staging of Muscle Invasive Bladder Cancer <i>Prodromos Philippou CY</i>	
18.40–19.00	How do we manage a patient with frequent recurrence of LG papillary tumours in the bladder despite intravesical chemotherapy and BCG therapy? <i>Chrysanthos Kouriefs CY</i>	
19.00–19.30	LB lecture: Utilization of genomic biomarkers for bladder cancer in clinical practice <i>Mohamad Moussa LB</i>	
19.30–20.00	Keynote Lecture <i>Chair: Vasilis Adamou</i> Entering and navigating the labyrinth of a long and fulfilling life as a doctor <i>Mikis Chistofides CY</i>	
20.00–20.40	Opening ceremony	
20.00	Welcome words <i>CAU: Stavros Charalampous / HUA: Athanasios Papatsoris</i> <i>SIU: Stavros Gravas / ICS: John Heeksackers / ESFU: Enrico Finazzi Agro</i> <i>PACS: Sheriff Mourad / LAU: Mohamad Moussa / INUS: Ch. Konstantinides</i>	
	<i>Chair: Stavros Charalampous</i> Public hygiene as a virtue in Limassol <i>Mimis Sofocleous</i> <i>Director, Patticheion Municipal Museum-Historical Archives and Research Centre of Limassol</i>	
20.45	Welcome Ceremony: Cheese & Wine	

Andrology Fertility

Chair: Chris Poulis, Fotios Dimitriadis

09.00–09.20 How common is male infertility, and what are its causes?
Konstantinos Constantinou **INUS LECTURE** [▶DELETE THIS](#)

09.20–09.40 Fertility and sexuality in the spinal cord injury patient
Charalampos Konstantinidis **INUS LECTURE**

09.40–10.00 Effect of oxidative stress on male reproduction
Euthymia Constantinou

Endourology

Chair: Dimitris Kontaxis, Panayiotis Sakkas

10.00–10.15 **Targeting Techniques in PCN & Serious Complications of PCNL**
Angelos Economides

10.15–10.40 **"Novel Disposable Mini RIRS"**
Athanasios Papatsoris

10.40–11.00 **The future in endoscopic stones surgery, tips & tricks**
Anastasis Anastasiadis


11.00–11.30 **COFFEE BREAK**  **CAU Elections**




11.30–12.30 **Prostate Cancer 2024 / HUA-CAU SESSION**
Chrysanthos Kouriefs, Theodoros Kalogeropoulos

11.30–11.50 **From morphology to genetic biomarkers.**
Andreas Mamillos

11.50–12.10 **What is the best imaging for diagnosis and follow up in Prostate Cancer:
MRI, CT, PET?**
Demetra Ziaka

12.10–12.30 **PROLARIS. The clinician's view.**
Athanasios Papatsoris **SPONSOR LECTURE** 

12.30–13.00 *Chair: Demetris Andreopoulos*
**The importance of early innervation with Apalutamide in the treatment
of mmCRPC**
Marinos Tsiatas **SPONSOR LECTURE** 

STATE OF THE ART LECTURES13.00–14.00 *Chair: Onay Yalcin, Vasileios Sakalis*13.00–13.20 ESFU LECTURE: OAB: how should we investigate our patients?
*Enrico Finazzi Agro IT*13.20–13.40 PACS LECTURE: Female reconstructive surgery, fistulas
*Sheriff Mourad EG*13.40–14.00 PACS LECTURE: Post-Radical Prostatectomy Incontinence
*Mohamed Salah EG*13.40–14.00 **LUNCH BREAK**16.00- 16.30 **Neurourology, Functional & reconstructive Urology***Chair: Stavros Charalampous*Management of patients with LUTS due to OAB and/or BPO
in modern clinical practice*Stavros Gravas CY* SPONSOR LECTURE 16.30–17.30 **CAU-HUA-ICS-PACS JOIN SESSION***Chairs: Zafiro Kyriazi, Charalampos Konstantinidis*16.30–16.45 Intermittent Clean Catheterizations: Save lives?
*Charalampos Thomas GR*16.45–17.00 Minimally invasive surgery in functional urology
*Vasilis Sakalis GR*17.00–17.20 Biomarkers, diagnostic & therapeutic modalities in Functional Urology
*Apostolos Apostolidis GR***STATE OF THE ART LECTURES continue**17.30–18.30 SIU LECTURE: *Chair: Stavros Gravas*
ECCHOLASER by ELESTA LASER ablation of the prostate for BPH. What is new?
*Mauro Gacci IT*18.00–18.30 **COFFEE BREAK** 18.30–19.00 *Chairs: Stavros Charalampous, Petros Tsafrakidis*
ICS LECTURE: Neuromodulation for refractory OAB
*John Heeksackers NL*19.00–19.30 Medical treatment of underactive treatment-realistic expectation or utopian
*Francisco Cruz PT*19.30–20.00 Virtual reality (VR), and the future of surgery urology
Elisabetta Costantini IT

Provides
powerful and
long-term efficacy^{1,2}

>40% of patients
achieved a $\geq 90\%$ reduction
IN INCONTINENCE EPISODES /week after 2 years

86% of
patients were *satisfied*
with **Emselex**[®] treatment⁴

Flexible dosing, *once daily*³

 **Emselex**[®]

Emselex Tablet, Prolonged – Release 15mg/L.T. (με ΦΠΑ): 34,97 ευρώ. Διατίθεται στο Γε2Υ με συνεισφορά II: 17,13 ευρώ
Emselex Tablet, Prolonged – Release 7,5mg/L.T. (με ΦΠΑ): 22,75 ευρώ. Διατίθεται στο Γε2Υ με συνεισφορά II: 10,40 ευρώ

Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή. Πριν την συνταγογράφηση, συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που υπάρχει διαθέσιμη στην ιστοσελίδα: <https://www.phs.moh.gov.cy/web/guest>
Για περισσότερες πληροφορίες, απευθυνθείτε στην Εταιρεία C.A.Papaellinas Group.

References:
1. Hill S et al. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:239-47.; 2. Haab F et al. BJU Int 2006; 98:1025-32.; 3. Emselex Summary of Product Characteristics 7/2015.; 4. Zinner N, et al. Int J Clin Pract 2008; 62: 166474.



ΣΚΑΝΑΡΕΤΕ ΓΙΑ ΤΟ SPC


C.A. PAPAELLINAS
GROUP

Τοπικός Αντιπρόσωπος Κύπρου C.A. Papaellinas Group

MARKETING AUTHORISATION HOLDER: ZR Pharma & GmbH, Rauhenssteingasse 10, 1010 Wien, Austria, Tel.: +43/1/3560006

Λεωφόρος Γιάννου Κρανιδιώτη 179, 2235, Λεττωά, Λευκωσία | Τηλ.: 22741741, www.cap.com.cy

Ems/Adv/01/Mar_24

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Α ναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Tostran®

γέλη τεστοστερόνης

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

Περαιτέρω πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως.

KYOWA KIRIN

ΤΟΠΙΚΟΣ ΑΝΤΙΠΡΟΣΩΠΟΣ

anaBIOsis
pharmaceuticals

ΑΝΑΒΙΩΣΙΣ ΙΚΕ

Αθήνα: Παράπλευρος Α, Κύμης 3-7, 141 22 Νέο Ηράκλειο Αττικής, Τ: 210 2711020-120, F: 210 2712001

Θεσσαλονίκη: 9ο χλμ. Θεσσαλονίκης-Μουδανιών, 555 35 Θεσσαλονίκη, Τ: 2310 489360, F: 2310 489396

E: info@anabiosis.gr • www.anabiosis.gr

Τρόπος διάθεσης: Χορηγείται με Ιατρική Συνταγή.

Διατίθεται μέσω του ΓΕΣΥ

Α.Τ. ΚΥΠΡΟΥ: €45,94 Συμπληρωμή II στο ΓΕΣΥ: €10,09

Πριν την συσκευασία συμβουλευτείτε την Περιγραφή των Χαρακτηριστικών του Προϊόντος που διατίθεται εδώ



09.00–10.00	BPH-Urinary incontinence Female <i>Chairs: Antonis Koumis, Ziad Milad</i>
09.00–09.15	Refractory OAB <i>Constantinos Tryfonos</i>
09.15–09.30	Stress incontinence with concurrent genital organ prolapse <i>Theocharis Tondikidis CY</i>
09.30–09.45	Holep technique developments <i>Marios Hatzipavlou CY</i>
09.45–10.00	BPH management in the office <i>Petros Tsafrakides CY</i>
10.00–10.30	EAU STATE OF THE ART LECTURE <i>Chair: Petros Tsafrakides</i> Modern management of bilateral renal cell carcinoma <i>Christian Schwentner DE</i>
10.30–11.30	Male LUTS & Erectile Dysfunction <i>Chairs: Costas Mavromatis, Spyros Eliades</i>
10.30–10.45	Conservative management of BPH & ED <i>Christodoulos Yerosimou CY</i>
10.45–11.00	Typical BPH with Symptoms and Significant Residual, High Pressure, Low Flow: Choice of Procedure - What Factors to Consider, What Procedure <i>Nicolas Nicolaou CY</i>
11.00–11.15	Young man with bladder neck obstruction; What Factors to Consider, What Procedure <i>Dimitris Costi CY</i>
11.15–11.30	Young men with Erectile Dysfunction; What factor to consider. <i>Constantinos Eliades CY</i>
	Closing remarks <i>Stavros Charalampous, Petros Tsafrakides</i>

PUSH BACK ON RESSION

By treating early with **ERLEADA**[®] + ADT, your patients with high-risk[†] nmCRPC could live for a median of more than **6 years**^{2*}

ERLEADA[®] is indicated for the treatment of adult men with:¹

- non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk[†] of developing metastatic disease
- metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT

nmCRPC - non-metastatic castration-resistant prostate cancer. NHT - novel hormonal therapy.

* Median OS was 73.9 months with ERLEADA[®] + ADT vs 59.9 months with PBO + ADT; HR=0.78; 95% CI, 0.64–0.96; P=0.016.²

† High risk is defined as patients with a PSA doubling time of ≤10 months.¹

References: 1. ERLEADA[®] (apalutamide). Summary of Product Characteristics. Available from: www.medicines.ie. 2. Smith MR, et al. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol*. 2021;79(1):150–158.

Για την περίληψη
χαρακτηριστικών
του προϊόντος Erleada,
σαρώστε



ERL/ADV/MAR2024/CY002 (CP-443647)



Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιαδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες.

ΟΝΟΜΑ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ	ΣΥΣΚΕΥΣΙΑ	ΔΡΑΣΤΙΚΟ ΣΥΣΤΑΤΩ	ΚΑΤΟΧΟΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ	ΕΞ. ΑΝΤΙΠΡΟΣΩΠΟΣ ΕΜΠΟΡΕΥΣΗΣ	ΜΕΓΙΣΤΗ ΔΥΝΑΤΗ ΙΑΝΚΗ ΣΤΗΝ ΜΕ ΦΠΑ
ERLEADA TABLET FILM COATED 60MG	PACK WITH 112 TABLETS IN BLISTER(S)	APALUTAMIDE	JANSSEN-Cilag INTERNATIONAL NV	ΥΠΟΥΡΓΟΣ ΥΓΕΙΑΣ ΚΑΔΙΠΑΝΑΥΙΣ LTD	2569.04

Αυτογράφος στην Κίρσο

VHP HADJIPANAYIS
Pharmaceutical Companies Ltd, 2214 Athens, Attica, Greece
Tel: +30210 32227100, Fax: +30210 32227108

Βοηθήστε να φέρουν τα φάρμακα πιο ασφαλή και
Ασφαλεία
ΟΜΕΣ τις αναπαραγωγικές ενέργειες για
ΟΜΑ τα φάρμακα
Συμβολοποιώντας την ΚΙΤΡΙΝΗ ΚΑΡΤΑ.

Κίτρινος όμιλος κυκλοφορίας

Janssen
Pharmaceutical Companies of Johnson & Johnson

Janssen Oncology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Symposium Venue

Atlantica Miramare Beach Hotel
11 Amerikanas Str. 4060 Yermasoyia,
Limassol, Cyprus
Tel: +357 25 881100

Symposium dates

April 19-21, 2024

Official Language

The Official Language of the Symposium
is Greek & English.

Registration Fees

Doctors 100EUR
Trainees 50EUR

Accommodation between 18-22/04/2024

Single room €90 B&B

Double room €110 B&B

Reservations Directly to the hotel

r.makridou@atlantichotels.com

c.panayiotou@atlantichotels.com

Registration Fees Include

- Admittance to all scientific sessions and to the exhibition
- Meeting documentation
- Certificate of attendance
- Coffee & refreshments during the Symposium breaks
- Admittance to the Opening ceremony

GALA dinner €50 per person.
Please book early to avoid any inconvenience.

Exhibition

During the Symposium an exhibition of pharmaceutical, medical products, research and technologies products will be organized by the sponsor companies.

Certificate of Attendance

Attendance certificates will be handed to those who attend at least 60% of the presentation.

Accreditation

The Symposium has been approved and registered within the EU-ACME programme with the total of **11 credits**.

Badges

A badge will be provided to all registered participants.

Symposium Organization Office

CYPRUS UROLOGICAL ASSOCIATION

Secretary: Stalo Papaioannou

Tel: +3572558771

office@cau.org.cy

Bank Account

KYPRIAKH OUROLOGIKI ETAIREIA

GENERAL HOSPITAL–NICOSIA

1450 NICOSIA

BANK OF CYPRUS ACCOUNT:

011 401015355

IBAN: CY30002001140000000101535500

BCYPCY2N



ΠΟΛΥΚΛΙΝΙΚΗ ΥΓΕΙΑ
Ιδιωτικό Νοσοκομείο
ΥΓΙΑ POLYCLINIC
Private Hospital

ΠΟΛΥΚΛΙΝΙΚΗ ΥΓΕΙΑ – 37 ΧΡΟΝΙΑ
ΣΥΝΕΧΟΥΣ ΠΡΟΣΦΟΡΑΣ ΣΤΟΝ ΑΣΘΕΝΗ ΚΑΙ ΣΤΗΝ ΚΟΙΝΩΝΙΑ
24ΩΡΗ ΕΞΥΠΗΡΕΤΗΣΗ, 7 ΗΜΕΡΕΣ ΤΗΝ ΕΒΔΟΜΑΔΑ ΕΝΤΟΣ ΓεΣΥ

ΠΛΕΟΝ ΤΩΝ 100 ΣΥΝΕΡΓΑΤΩΝ ΚΑΙ 55 ΕΣΩΤΕΡΙΚΩΝ ΙΑΤΡΩΝ ΟΛΩΝ ΤΩΝ ΕΙΔΙΚΟΤΗΤΩΝ
ΤΕΛΕΥΤΑΙΑΣ ΤΕΧΝΟΛΟΓΙΑΣ ΔΙΑΓΝΩΣΤΙΚΟ ΤΜΗΜΑ
ΠΛΗΡΩΣ ΕΞΟΠΛΙΣΜΕΝΗ ΕΝΤΑΤΙΚΗ ΜΟΝΑΔΑ ΘΕΡΑΠΕΙΑΣ
ΜΟΝΑΔΑ ΚΑΘΗΤΗΡΙΑΣΜΩΝ ΚΑΡΔΙΑΣ
ΕΝΔΟΣΚΟΠΙΚΟ ΤΜΗΜΑ
ΠΑΙΔΙΑΤΡΙΚΟ – ΠΑΙΔΟΧΕΙΡΟΥΡΓΙΚΟ ΤΜΗΜΑ
ΜΑΙΕΥΤΙΚΟ – ΓΥΝΑΙΚΟΛΟΓΙΚΟ ΤΜΗΜΑ
ΧΕΙΡΟΥΡΓΙΚΟ ΤΜΗΜΑ
EYE LASER CENTER

ΔΙΑΠΙΣΤΕΥΜΕΝΟ ΚΑΙ ΠΙΣΤΟΠΟΙΗΜΕΝΟ ΝΟΣΟΚΟΜΕΙΟ
ΑΠΟ ΤΟΥΣ ΠΛΕΟΝ ΕΓΚΡΙΤΟΥΣ ΔΙΕΘΝΕΙΣ ΟΙΚΟΥΣ

Accredited by



- Andreopoulos Demetris** *Radioogologist, Aretaieion Hospital, Nicosia, CY*
- Alevroudis Emmanouil** *Nuclear Medicine Consultant, German Medical Center, Limassol, CY*
- Anastasiades Anastasios** *Professor of Urology, Aristoteles University Thessaloniki, GR*
- Charalampous Stavros** *Urologist, Institute of Functional & Reconstructive Urology Limassol, CY*
- Charalampous Charis** *Oncologist, Bank of Cyprus Ongology center, Nicosia, CY*
- Christofides Mikis** *Urologist, Apollonion Hospital Nicosia, CY*
- Constantinou Efthymia** *Genetics, Institute Of Neurology, Nicosia, CY*
- Costi Demetris** *Urologist, Aretaieion Hospital Nicosia, CY*
- Dimitriades Fotios** *Professor of Urology, Aristotles University of Thessaloniki, GR*
- Economides Angelos** *Urologist, Bleu Cross Clinic Paphos, CY*
- Eliades Constantinos** *Urologist, Gen. Hospital Paphos, CY*
- Eliades Spyros** *Urologist, Sinesion Medical Center Larnaca, CY*
- Gravas Stavros** *Professor of Urology, Cyprus University Nicosia, CY*
- Hadjipavlou Marios** *Urologist, Policlinic Nicosia, CY*
- Kalogeropoulos Theodoros** *Urologist, Ippokrateio Gen Hospital Athens, GR*
- Karaolides Theocharis** *Urologist Gen Hospital Nicosia, CY*
- Kitsios Petros** *Ongologist-Radiologist, Nicosia, CY*
- Konstantinidis Charalampos** *Urologist, Urology & Neurourology National Rehabilitation Center Athens, GR*
- Kontaxis Demetrios** *Urologist, Policlinic Limassol, CY*
- Koumis Antonis** *Urologist, Limni Medical Clinic Paralimni, CY*
- Kouriefs Chrysanthos** *Urologist, Ygeia Polyclinic, Limassol, CY*
- Kyriazi Zaphiro** *Urologist, Gen Hospital Nicosia, CY*
- Kyriakides Andreas** *Urologist, Nicosia Gen Hospital, Nicosia, CY*
- Malas Simos** *Ongologist Limassol General Hospital, CY*
- Mamilos Andreas** *Consultant Histopathologist German Medical Center Limassol, CY*
- Milad Ziad** *Urologist, General Hospital Nicosia, CY*
- Nicolas Nicolaou** *Urologist, Gen Hospital Nicosia, CY*
- Papatsoris Athanasios** *Professor of Urology, National & Kapodistrian University Athens, GR*
- Philippou Prodromos** *Urologist, Apolloneion Hospital Nicosia, CY*
- Poulis Chris** *Urologist, American Medical Center, Nicosia, CY*
- Sakalis Vasilios** *Urologist, Ippokratio Hospital, Thessaloniki, GR*
- Sakkas Panagiotis** *Urologist, Simos Kyriakides Clinic, Larnaca, CY*
- Thomas Charalampos** *Urologist, General Hospital, Korinthos, GR*
- Tontikidis Theacharis** *Urologist, General Hospital Larnaca, CY*
- Tsiatas Marinos** *Medical Oncologist Dir. Medical Oncology Dept & Clinical Trials Unit of Athens Medical Group, GR*
- Tsarakides Petros** *Urologist, German Medical Center Limassol, CY*
- Vomvas Demitrios** *Radiologist, Ongology Center Bank of Cyprus Nicosia, CY*
- Yerosimou Christodoulos** *Urologist, Diktaion Medical Center Nicosia, CY*
- Ziaka Demetra** *Radiologist, Agios Therissos Nicosia, CY*



BetmigaTM

mirabegron



BET/ADV 1/06/23

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναστήστε
ΟΜΕΣ τις αντιβιοτικές εναρτήσεις, να ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ».

ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ ΓΙΑ ΤΟ ΟΠΟΙΟ ΑΠΑΙΤΕΙΤΑΙ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ

Ελλάδα

Betmiga 25 mg δισκία παρατεταμένης αποδέσμευσης, ΛΤ 42,36€
Betmiga 50 mg δισκία παρατεταμένης αποδέσμευσης, ΛΤ 32,73€

Κύπρος

Betmiga 25 mg δισκία παρατεταμένης αποδέσμευσης, 45,74€
Betmiga 50 mg δισκία παρατεταμένης αποδέσμευσης, 40,79€

Για περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ, κατόπιν απήχησης, ή περιλαμβάνονται στη
συνεπική περιγραφή χαρακτηριστικών του προϊόντος, το Φύλλο Οδηγιών Χρήσης του φαρμάκου.



Astellas Pharmaceuticals A.E.B.E.
Αγησιόλου 6-8, 151 23 Μαρούσι, Αθήνα.
Τηλ. 210 8189 900, Fax: 216 8008 998
www.astellas.com.gr

Τοπικός Αντιπρόσωπος/
Διανομέας προϊόντων Astellas στην Κύπρο:
Novagem Ltd, Τηλ: 00357 22483858

Prof. Apostolos Apostolidis

Prof. of Urology-Neurourology at Aristotle University of Thessaloniki, Greece

Prof. John PFA Heesakkers; MBA, MD, PhD

*Full Professor at Maastricht University and as Head of the Department of Urology of the Maastricht UMC, the Netherlands
General Secretary of the International Continence Society*

Prof. Elisabeta Constantini

Professor of Andrological and Urogynecological Clinic - AOU Terni and Perugia, Coordinator Doctorate in Translational Medicine and Surgery Dept of Surgical and Biomedical Science, University of Perugia, Italy

Prof. Enrico Finazzi Agrò

Full Professor of Urology, Dept. of Surgical Sciences, University of Rome "Tor Vergata", Director of the Unit of Urology, Policlinico Tor Vergata University Hospital, Trustee of the International Continence Society, Board Member the European Association of Urology (EAU), Section of Functional Urology (ESFU), Rome, Italy

Prof. Francisco Cruz, MD, PhD

Professor and Chairman of Urology, Hospital S João and Faculty of Medicine of Porto, Portugal

Dr Mauro Gacci

Professor of Urology, University of Florence, AOUC Careggi Hospital, Florence, Italy

Prof. Mohamad Moussa

*Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon, Urology MD, F.E.B.U.
Prof. of Urology, Dean of the Faculty of Medicine, Lebanese University, Chairman of the Surgery Department*

Prof. Onay Yalcin

Prof. of Gynaecology, Istanbul University Istanbul School of Medicine, from Cyprus

Prof. Mohamed Salah

*Professor at Cairo University, Prof. of Urology and Head of Female Urology and Voiding dysfunction Unit,
Cairo University Faculty of Medicine, Egypt*

Dr Sheriff Mourad, MD, PhD

*Prof. of Urology, Ain Shams University, Cairo, Egypt, Chairman of Katameya Clinic for Medical Services - KC Hospitals -
New Cairo, Egypt, General Secretary of Egyptian Urological Association (EUA), Board Director of Egyptian Urological
Guidelines (EUG), Chair of ICS Committee of Developing World, Bristol, UK
Honorary President of Pan Arab Continence Society (PACS)*

Prof. Christian Schwentner

Professor of Urology, University of Tuebingen, Tübingen Germany





UROREC[®] Silodosin

UROREC[®] Silodosin

URO101/CY/09-2022



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και αναφέρετε **ΟΛΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα συμπληρώνοντας την «**KITPINH KAPTA**»



Papaloizou

35 Kilkis Avenue, 2234 Latsia, Cyprus
Tel: 22 490305 | Fax: 22 490308
www.papaloizou.com

Για συνταγογραφικές πληροφορίες ανατρέξτε στην ιστοσελίδα www.papaloizou.com

Θέτουμε
τη γενετική
στο επίκεντρο των
ιατρικών
αποφάσεων

ΚΑΙΝΟΤΟΜΕΣ ΓΕΝΕΤΙΚΕΣ ΕΞΕΤΑΣΕΙΣ ΟΓΚΟΛΟΓΙΑΣ

- Καινοτόμος Εξέταση Υγρής Βιοψίας για Επιλογή Θεραπείας
- Εξειδικευμένες Εξετάσεις Προφίλ του Όγκου
- Λεπτομερής Γονιδιακή Ανάλυση Κληρονομικών Καρκίνων

PreSENTIA
hereditary cancer

ForeSENTIA
tumor profile

NeoThetis
therapy selection

T-Sling[®] PP



Technology to
the service
of health



distributed by:



ES Vascular Ltd
Berengaria 25, 4th Floor
25 Spyrou Araouzou, 3036 Limassol, Cyprus
T. +357 25040500 F. +357 25040444
W. www.esvascular.com